ANOAT THERAPEUTICS
French tech company | Builders Republic
About
Pre-clinical biotech developing antisense oligonucleotide therapies for cystic fibrosis — targeting an alternative chloride channel to compensate for defective CFTR protein activity in patients ineligible for or unresponsive to existing CFTR modulators.
Key facts
- Status
- Morte
- Sectors
- Healthcare & Life Sciences
- Latest stage
- Seed
- Founded
- 2023
- City
- PARIS
- Region
- IDF
- Tracked rounds
- 1
- Amount raised
- 2.0 M€ raised since 2020
Funding rounds
- Seed — 2023
Investors
- AdBio partners
- Inserm Transfert Initiative
Notes
Biotech préclinique ASO (mucoviscidose), créée en 2023; inactive depuis le 05/06/2024, dissoute avec liquidateur.